Compare LOOP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOOP | CGTX |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 132.4M |
| IPO Year | N/A | 2021 |
| Metric | LOOP | CGTX |
|---|---|---|
| Price | $1.02 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 73.4K | ★ 896.2K |
| Earning Date | 01-15-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,112,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $41.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10901.98 | N/A |
| 52 Week Low | $0.85 | $0.22 |
| 52 Week High | $2.29 | $3.83 |
| Indicator | LOOP | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 46.72 |
| Support Level | $0.95 | $1.33 |
| Resistance Level | $1.04 | $1.62 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 69.08 | 32.56 |
Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.